Consensus Repligen Corporation

Stocks

RGEN

US7599161095

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 04:21:55 05/08/26 am AEST			5-day change	1st Jan Change
147.46 ^USD	+0.27%		+1.40%	-10.06%

30/07	Repligen's Diversity of Growth Drivers Support Return to Mid-Teens Organic Sales Growth, RBC Says	MT
29/07	RBC Raises Price Target on Repligen to $185 From $160, Keeps Outperform Rating	MT

Evolution of the Average Target: Repligen Corporation

Evolution of the Target Price: Repligen Corporation

Changes in Analyst Recommendations: Repligen Corporation

5ccacd1482.aXgGJGoTS9saYELBQpiF4ZrOzNvKwx13FvLVVON11uY.ODxHUltEH41iUim0Kd_1oreMuJDzkihPWLqtYo8vpIEsQVdXDEkgjUsPeg~5e39be2261dcaf30274b0ef2efab00ce

Analysts' recommendations: Repligen Corporation

30/07	Repligen's Diversity of Growth Drivers Support Return to Mid-Teens Organic Sales Growth, RBC Says	MT
29/07	RBC Raises Price Target on Repligen to $185 From $160, Keeps Outperform Rating	MT
29/07	Deutsche Bank Adjusts Repligen Price Target to $200 From $180, Maintains Buy Rating	MT
07/07	Benchmark Upgrades Repligen to Buy From Hold, Price Target is $185	MT
16/05	Repligen Likely to Benefit From Diverse Growth Factors, RBC Says	MT
17/04	Rothschild & Co Redburn Initiates Repligen at Buy With $160 Price Target	MT
26/02	UBS Adjusts Price Target on Repligen to $195 From $200, Maintains Buy Rating	MT
17/01	UBS Adjusts Price Target on Repligen to $200 From $190, Maintains Buy Rating	MT
01/10/25	HSBC Initiates Repligen at Buy With $150 Price Target	MT
23/09/25	Repligen Shares Rise After Upgrade From Evercore ISI	MT
22/09/25	Evercore ISI Upgrades Repligen to Outperform From In Line, Price Target is $155	MT
03/09/25	RBC Lifts Price Target on Repligen to $205 From $204, Keeps Outperform Rating	MT
30/07/25	RBC Raises Price Target on Repligen to $204 From $193, Keeps Outperform Rating	MT
29/07/25	Life sciences firm Repligen beats Q2 revenue estimates, raises full-year guidance	RE
01/07/25	RBC Lifts Price Target on Repligen to $193 From $191, Keeps Outperform Rating	MT
24/06/25	Barclays Initiates Repligen at Overweight With $150 Price Target	MT
30/04/25	RBC Lowers Price Target on Repligen to $189 From $202, Keeps Outperform Rating	MT
30/04/25	Wolfe Research Upgrades Repligen to Outperform From Peerperform	MT
08/04/25	RBC Cuts Price Target on Repligen to $202 From $219, Keeps Outperform Rating	MT
18/03/25	Evercore ISI Initiates Repligen at In Line With $155 Price Target	MT
21/02/25	RBC Raises Price Target on Repligen to $205 From $203, Keeps Outperform Rating	MT
21/02/25	Deutsche Bank Adjusts Repligen Price Target to $195 From $190, Maintains Buy Rating	MT
10/02/25	TD Cowen Initiates Repligen at Buy With $200 Price Target	MT
04/02/25	RBC Trims Price Target on Repligen to $203 From $207, Keeps Outperform Rating	MT
09/12/24	RBC Lifts Price Target on Repligen to $207 From $205, Keeps Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	REPLIGEN CORPORATION					+26.28%
	ABBOTT LABORATORIES					+10.55%
	MEDTRONIC PLC					+13.57%
	CENCORA, INC.					+15.66%
	HOYA CORPORATION					+20.27%
	BECTON, DICKINSON AND COMPANY					+5.9%
	MEDLINE INC.					+25.16%
	DEXCOM, INC.					+7.02%
	WEST PHARMACEUTICAL SERVICES, INC.					+16.32%
	STERIS PLC					+9.77%
	Average					+15.05%
	Weighted average by Cap.					+13.28%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

147.06USD

Average target price

185.70USD

Spread / Average Target

+26.27%

High Price Target

220.00USD

Spread / Highest target

+49.60%

Low Price Target

145.00USD

Spread / Lowest Target

-1.40%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
Deutsche Bank Securities
Benchmark Company
Rothschild & Co Redburn
UBS
HSBC
Evercore ISI
Barclays
Wolfe Research
TD Cowen
Guggenheim
KeyBanc Capital Markets
Craig-Hallum
JPMorgan Chase
Stephens Inc.
Wells Fargo Securities
Stifel Nicolaus
SVB Securities LLC
SVB Leerink
Exane BNP Paribas
William O'Neil & Co
HC Wainwright